Barinthus Bio to Merge with Clywedog in All-Stock Deal
New company to focus on advancing a clinical-stage pipeline targeting diabetes and autoimmune diseases.
Barinthus Biotherapeutics (NASDAQ: BRNS) has entered into a to combine with Clywedog Therapeutics in an all-stock transaction. The deal will create a new entity focused on developing treatments for metabolic and autoimmune disorders, a move designed to leverage a promising pipeline of clinical-stage candidates.
The combined company will be renamed Clywedog Therapeutics, Inc. and is expected to trade on the Nasdaq under the new ticker symbol 'CLYD'. Per the terms of the agreement, current Barinthus shareholders will own approximately 34% of the new company, with Clywedog stockholders holding the remaining 66%.
The strategic combination centers on advancing a targeting Type 1 and Type 2 Diabetes, as well as Celiac Disease. Leadership has highlighted an ambitious timeline, with four significant clinical data milestones anticipated within 18 months of the transaction's closing.
Financially, the combined entity is projected to have a robust cash position, with a runway expected to fund operations through 2027. This financial stability is crucial as the company works to advance its therapeutic programs through key clinical trials. The merger has received backing from Clywedog’s existing shareholders, including prominent life science investors OrbiMed and Torrey Pines Investment LLC.
, providing continuity in leadership through the transition. The merger is projected to close in the first half of 2026, subject to customary closing conditions and shareholder approval. Investors will be closely watching for the upcoming clinical milestones as the new company, Clywedog Therapeutics, takes shape.